MCID: ERY066
MIFTS: 29

Erythema Multiforme Major

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Erythema Multiforme Major

MalaCards integrated aliases for Erythema Multiforme Major:

Name: Erythema Multiforme Major 59 72
Erythema Exsudativum Multiforme Majus 59
Erythema Multiforme Majus 59
Stevens-Johnson Syndrome 72

Classifications:

Orphanet: 59  
Rare skin diseases


External Ids:

Orphanet 59 ORPHA502499
UMLS 72 C0038325 C3241919

Summaries for Erythema Multiforme Major

MalaCards based summary : Erythema Multiforme Major, also known as erythema exsudativum multiforme majus, is related to erythema multiforme and severe cutaneous adverse reaction. The drugs Gabapentin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes.

Related Diseases for Erythema Multiforme Major

Diseases related to Erythema Multiforme Major via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 47, show less)
# Related Disease Score Top Affiliating Genes
1 erythema multiforme 11.8
2 severe cutaneous adverse reaction 10.5
3 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.5
4 exanthem 10.4
5 herpes simplex 10.3
6 stevens-johnson syndrome/toxic epidermal necrolysis 10.3
7 vascular disease 10.2
8 neutropenia 10.1
9 skin disease 10.1
10 bullous pemphigoid 10.1
11 pemphigus 10.1
12 autoimmune disease 10.0
13 major affective disorder 1 10.0
14 renal cell carcinoma, nonpapillary 10.0
15 immune deficiency disease 10.0
16 yemenite deaf-blind hypopigmentation syndrome 10.0
17 meningioma, radiation-induced 10.0
18 meningioma, familial 10.0
19 nail disorder, nonsyndromic congenital, 10 10.0
20 chlamydia pneumonia 10.0
21 pemphigus gestationis 10.0
22 disseminated intravascular coagulation 10.0
23 chlamydia 10.0
24 spinal meningioma 10.0
25 cicatricial pemphigoid 10.0
26 allergic hypersensitivity disease 10.0
27 locked-in syndrome 10.0
28 quadriplegia 10.0
29 pemphigoid gestationis 10.0
30 thrombocytopenia 10.0
31 melanoma 10.0
32 focal epilepsy 10.0
33 systemic scleroderma 10.0
34 secretory meningioma 10.0
35 lymphoplasmacyte-rich meningioma 10.0
36 pneumonia 10.0
37 conjunctivitis 10.0
38 acquired immunodeficiency syndrome 10.0
39 epilepsy with generalized tonic-clonic seizures 10.0
40 impetigo 10.0
41 herpes zoster 10.0
42 crohn's disease 10.0
43 alopecia areata 10.0
44 alopecia 10.0
45 neisseria meningitidis infection 10.0
46 bullous impetigo 10.0
47 acute liver failure 10.0

Graphical network of the top 20 diseases related to Erythema Multiforme Major:



Diseases related to Erythema Multiforme Major

Symptoms & Phenotypes for Erythema Multiforme Major

Drugs & Therapeutics for Erythema Multiforme Major

Drugs for Erythema Multiforme Major (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 123, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Azithromycin Approved Phase 4 83905-01-5 447043 55185
3
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
4
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
5
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
8 Ophthalmic Solutions Phase 4
9 Antimetabolites Phase 4
10 Anti-Bacterial Agents Phase 4
11 Analgesics Phase 4
12 Analgesics, Non-Narcotic Phase 4
13 Psychotropic Drugs Phase 4
14 Tranquilizing Agents Phase 4
15 Central Nervous System Depressants Phase 4
16 Anti-Anxiety Agents Phase 4
17 Excitatory Amino Acid Antagonists Phase 4
18 Anticonvulsants Phase 4
19 Antimanic Agents Phase 4
20 Excitatory Amino Acids Phase 4
21 Analgesics, Opioid Phase 4
22 Cytochrome P-450 Enzyme Inducers Phase 4
23 Lipid Regulating Agents Phase 4
24 Hypolipidemic Agents Phase 4
25 Peripheral Nervous System Agents Phase 4
26 Neurotransmitter Agents Phase 4
27 Diuretics, Potassium Sparing Phase 4
28 Sodium Channel Blockers Phase 4
29 Autonomic Agents Phase 4
30 Anti-Arrhythmia Agents Phase 4
31 Adrenergic beta-Antagonists Phase 4
32 Adrenergic Agents Phase 4
33 Adrenergic Antagonists Phase 4
34 Sympatholytics Phase 4
35
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616 46835353
36
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
37
Lesinurad Approved, Investigational Phase 3 878672-00-5 53465279
38
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
39
Etravirine Approved Phase 3 269055-15-4 193962
40
tannic acid Approved Phase 2, Phase 3 1401-55-4
41
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
42
Maraviroc Approved, Investigational Phase 2, Phase 3 376348-65-1 3002977
43
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
44
Etanercept Approved, Investigational Phase 3 185243-69-0
45
Coal tar Approved Phase 3 8007-45-2
46
Lamotrigine Approved, Investigational Phase 2, Phase 3 84057-84-1 3878
47
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
48 Hypoglycemic Agents Phase 3
49 Antirheumatic Agents Phase 3
50 Renal Agents Phase 3
51 Cytochrome P-450 CYP3A Inducers Phase 3
52 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
53 Cytochrome P-450 Enzyme Inhibitors Phase 3
54 Nucleic Acid Synthesis Inhibitors Phase 3
55 Cytochrome P-450 CYP2C19 Inhibitors Phase 3
56 Reverse Transcriptase Inhibitors Phase 3
57 Anti-Infective Agents Phase 2, Phase 3
58 Antiviral Agents Phase 2, Phase 3
59 Anti-Retroviral Agents Phase 2, Phase 3
60 Anti-HIV Agents Phase 2, Phase 3
61 HIV Fusion Inhibitors Phase 2, Phase 3
62 Immunologic Factors Phase 3
63 Pharmaceutical Solutions Phase 3
64 Antifungal Agents Phase 3
65 Immunosuppressive Agents Phase 3
66 Cyclosporins Phase 3
67 Calcineurin Inhibitors Phase 3
68 Anti-Inflammatory Agents, Non-Steroidal Phase 3
69 Emollients Phase 3
70 calcium channel blockers Phase 2, Phase 3
71 Antipsychotic Agents Phase 2, Phase 3
72 Calcium, Dietary Phase 2, Phase 3
73
Amoxicillin Approved, Vet_approved Phase 1, Phase 2 26787-78-0 33613
74 Hemostatics Phase 1
75 Fibrin Tissue Adhesive Phase 1
76 Coagulants Phase 1
77 Anesthetics, Local Phase 1
78 Anesthetics Phase 1
79
Allopurinol Approved 315-30-0 2094
80
Metformin Approved 657-24-9 4091 14219
81
Glyburide Approved 10238-21-8 3488
82
Prednisolone phosphate Approved, Vet_approved 302-25-0
83
Methylprednisolone hemisuccinate Approved 2921-57-5
84
Methylprednisolone Approved, Vet_approved 83-43-2 6741
85
Prednisolone Approved, Vet_approved 50-24-8 5755
86
Isotretinoin Approved 4759-48-2 5282379 5538
87
Carbamazepine Approved, Investigational 298-46-4 2554
88
Eslicarbazepine acetate Approved 75970-99-9, 236395-14-5 123618
89
Formaldehyde Approved, Vet_approved 50-00-0 712
90
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
91
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved 83-88-5 493570
92
Prednisolone hemisuccinate Experimental 2920-86-7
93 Liver Extracts
94 Free Radical Scavengers
95 Antioxidants
96 Dipeptidyl-Peptidase IV Inhibitors
97 HIV Protease Inhibitors
98 Sitagliptin Phosphate
99 Incretins
100
protease inhibitors
101 Protective Agents
102 Neuroprotective Agents
103 Antiemetics
104 Methylprednisolone Acetate
105 Antineoplastic Agents, Hormonal
106 Prednisolone acetate
107 Autoantibodies
108 Immunoglobulin A
109 Micronutrients
110 Trace Elements
111 Vitamins
112 Vitamin B9
113 Vitamin B Complex
114 Folate
115 Vitamin B2
116 Nutrients
117 Photosensitizing Agents
118 Dextrans
119 Antibodies
120 gamma-Globulins
121 Immunoglobulins
122 Immunoglobulins, Intravenous
123 Rho(D) Immune Globulin

Interventional clinical trials:

(showing 52, show less)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
3 Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction Completed NCT01977937 Phase 4 Gabapentin 250mg/5mL NDC:59762-5025-01;Simple Syrup
4 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
5 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
6 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
7 Transdermal Lidocaine Patch for Post-Cesarean Pain Control for Women With Obesity: a Single-blind Randomized Controlled Trial Recruiting NCT03810235 Phase 4 Transdermal Lidocaine Patch;Transdermal Hydrocolloid Placebo Patch
8 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
9 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
10 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
11 Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction Completed NCT01237600 Phase 2, Phase 3
12 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
13 A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor Completed NCT01508702 Phase 3 lesinurad;Placebo
14 A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125. Completed NCT00792324 Phase 3 Etravirine;Efavirenz
15 Maraviroc to Augment Rehabilitation Outcomes After Stroke Recruiting NCT03172026 Phase 2, Phase 3 Maraviroc 300 mg;Placebo 300 mg
16 Phase III Randomized Trial of the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Comparing Supportive Care, Cyclosporine, and Biologic Therapy in Adults Not yet recruiting NCT02987257 Phase 3 cyclosporin A;Etanercept 50 MG Solution for Injection;Placebos
17 Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study Terminated NCT00295776 Phase 2, Phase 3 Lamictal in the treatment of Post-Herpetic Neuralgia
18 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
19 Evaluation the Effect of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Epithelium Healing (Phase I and II Clinical Trial) Completed NCT02746848 Phase 1, Phase 2
20 Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-Centre Randomized Double Blind Controlled Trial in Pakistan Completed NCT00130013 Phase 1, Phase 2 Oral Amoxicillin
21 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
22 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
23 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
24 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
25 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
26 Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of Ocular Surface Reconstruction Completed NCT00344201 Phase 1
27 Topical Infliximab for the Treatment of Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
28 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Not yet recruiting NCT03878771 Phase 1 Dermovate cream in Orabase
29 Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction and Correlation With Disease Severity. Unknown status NCT03166241
30 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
31 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
32 The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation Unknown status NCT00696982 sitagliptin;glibenclamide
33 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
34 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
35 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions (SCAR) Completed NCT01276314 anti- TNF-a;Prednisolone
36 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
37 Evaluation of Immune Responses to Different Antigens in Non Infectious Ocular Inflammatory Diseases Completed NCT00357071
38 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
39 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
40 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Recruiting NCT02574988
41 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Recruiting NCT02795143 Isotretinoin
42 The Effects of Autologous Simple Limbal Epithelial Transplantation. Recruiting NCT04021875
43 The Effects of Allogeneic Simple Limbal Epithelial Transplantation Recruiting NCT04021134
44 HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions: a Multicenter Clinical Study Recruiting NCT03184597
45 An Exploratory Case-Control Study of Genetic and Clinical Factors for Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
46 Corneal Collagen Crosslinking to Increase the Resistance of the Graft Used as a Support for the Boston Keratoprosthesis Type I Against Corneal Melting Recruiting NCT03041883
47 Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria (SALIENT-A) Recruiting NCT03445312
48 An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients Available NCT02149732
49 A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT03585946 Site specific standard of care comparison
50 The Use of Pentacam in Assessment of Corneal Changes After Pterygium Excision Not yet recruiting NCT03304366
51 Heidelberg Retina Tomograph (HRT) in Vivo Confocal Microscopy to Evaluate the Ocular Surface Disorders of Healthy and Diseased Individuals Not yet recruiting NCT04025801
52 Histologic Evaluation Comparing Power Settings in Radiofrequency Ablation on Eyelash Follicles Not yet recruiting NCT03947723

Search NIH Clinical Center for Erythema Multiforme Major

Genetic Tests for Erythema Multiforme Major

Anatomical Context for Erythema Multiforme Major

MalaCards organs/tissues related to Erythema Multiforme Major:

41
Skin, Eye, Testes, T Cells, Liver, Lung, Salivary Gland

Publications for Erythema Multiforme Major

Articles related to Erythema Multiforme Major:

(showing 3381, show less) <
# Title Authors PMID Year
1
Stevens Johnson syndrome and toxic epidermal necrolysis - an Australian analysis of treatment outcomes and mortality. 38
30632424 2019
2
Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. 38
30086678 2019
3
Predicting sepsis in Stevens-Johnson syndrome-toxic epidermal necrolysis: Should dermatologists be pro-procalcitonin? 38
31420075 2019
4
Histomorphological Changes in Lachrymal Glands of Patients With Chronic Stevens-Johnson Syndrome. 38
31232745 2019
5
Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. 38
30809807 2019
6
Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. 38
30825193 2019
7
Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma. 38
31198688 2019
8
Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review. 38
31150704 2019
9
Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients. 38
31195022 2019
10
Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. 38
31254013 2019
11
Severe Cutaneous Adverse Reactions to Antiepileptic Drugs: A Nationwide Registry-Based Study in Korea. 38
31332981 2019
12
Microbial Keratitis in Stevens-Johnson Syndrome: A Prospective Study. 38
30998617 2019
13
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus. 38
29912772 2019
14
Contribution to oral and maxillary surgery and surgical technique of osteo-odontokeratoprosthesis in Japan. 38
31378404 2019
15
Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know. 38
30785787 2019
16
Stevens-Johnson Syndrome and Treatment With Clopidogrel. 38
30119955 2019
17
Altered retinoid metabolism gene expression in chronic Stevens-Johnson syndrome. 38
31023710 2019
18
Incomplete Stevens-Johnson Syndrome Caused by Sulfonamide Antimicrobial Exposure. 38
31404173 2019
19
Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review. 38
31436331 2019
20
Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database. 38
31041733 2019
21
Nursing problems in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome in a Dutch burn centre: A 30-year retrospective study. 38
31387802 2019
22
Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-2016: a four-source capture-recapture estimate. 38
31396952 2019
23
Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. 38
30918988 2019
24
Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity. 38
31434673 2019
25
Drug hypersensitivity in HIV infection. 38
31145192 2019
26
HLA-B*58:01 Genotyping to Prevent Cases of DRESS and SJS/TEN in East Asians Treated with Allopurinol-A Canadian Missed Opportunity. 38
31378082 2019
27
Long-term effect of corneoscleral contact lenses on refractory ocular surface diseases. 38
30389416 2019
28
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. 38
31387950 2019
29
A review and guide to drug-associated oral adverse effects-Oral mucosal and lichenoid reactions. Part 2. 38
31241804 2019
30
Identification of drug-specific public TCR driving severe cutaneous adverse reactions. 38
31395875 2019
31
Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. 38
31020549 2019
32
Making a diagnosis in severe cutaneous drug hypersensitivity reactions. 38
31247634 2019
33
[Warning symptoms skin: cutaneous manifestation of drug allergy]. 38
31282839 2019
34
Corneal higher-order aberrations in Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
31325631 2019
35
[Allergies to non-betalactam antibiotics: a challenge in practice]. 38
31282834 2019
36
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. 38
31327687 2019
37
Ocular manifestations in patients with Stevens-Johnson syndrome in Malawi-review of the literature illustrated by clinical cases. 38
31352606 2019
38
Long-term impact of a treatment protocol for acute ocular involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
31326519 2019
39
Clinical Outcome of Autologous Cultivated Oral Mucosal Epithelial Transplantation in Ocular Surface Reconstruction. 38
31356413 2019
40
Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond. 38
31384575 2019
41
Erythema Multiforme: Recognition and Management. 38
31305041 2019
42
Intravenous cyclosporine in treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis: A case series. 38
31070856 2019
43
Multistep Grading System for Evaluation of Chronic Ocular Sequelae in Patients With Stevens-Johnson Syndrome. 38
30731084 2019
44
Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor. 38
31342541 2019
45
Depletion of regulatory FoxP3+ T cells in the pathogenesis of Stevens-Johnson syndrome induced by mogamulizumab. 38
31334834 2019
46
Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and HLA-B*58:01 Genotype. 38
31308200 2019
47
How different is Stevens-Johnson syndrome/toxic epidermal necrolysis in children? 38
31259411 2019
48
A case of recurrent Stevens-Johnson syndrome caused by nivolumab therapy. 38
31290394 2019
49
Coxsackievirus B5-induced severe mucocutaneous reaction mimicking drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
31062724 2019
50
Dark skin phototype is associated with more severe ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
30633324 2019
51
Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature. 38
30659711 2019
52
Comment on 'Bronchiolitis obliterans as a long-term sequela of Stevens-Johnson syndrome and toxic epidermal necrolysis in children'. 38
31323139 2019
53
The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 38
31365024 2019
54
The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-Reply. 38
31365027 2019
55
International and multidisciplinary scientific collaborations and networks are advancing knowledge about Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
31259394 2019
56
Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
30613954 2019
57
Trends in mortality rates for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): experience of a single center in France between 1997 and 2017. 38
31323695 2019
58
British Association of Dermatologists' guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. 38
30829411 2019
59
Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States. 38
31158306 2019
60
Direct in situ labeling of target drugs with a fluorophore probe to improve MALDI-MS detection sensitivity in micro-liter plasma. 38
31346224 2019
61
Individual and hospital-level factors associated with epidermal necrolysis mortality: a Nationwide Multi-Level Study, France, 2012-2016. 38
31260078 2019
62
Genetic testing for prevention of severe drug-induced skin rash. 38
31314143 2019
63
Recurrent erythema multiforme major in an 8-year-old patient with recurrence of herpetic gingivostomatitis and HLA-B*5801 haplotype: A causal or casual relationship? 38
31341940 2019
64
Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study. 38
31166019 2019
65
Mucosal Lichen Planus Mimicking Mucosal Lesions in Stevens-Johnson Syndrome after Nivolumab Therapy. 38
30938822 2019
66
Characteristics of meibomian gland dysfunction in patients with Stevens-Johnson syndrome. 38
31261544 2019
67
Glaucoma Management in Patients with Aniridia and Boston Type 1 Keratoprosthesis. 38
31247168 2019
68
Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: Subgroup analysis based on a Japanese spontaneous database. 38
31231846 2019
69
Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. 38
30242287 2019
70
Stevens-Johnson syndrome and toxic epidermal necrolysis - retrospective review of cases in a high complexity hospital in Brazil. 38
31173347 2019
71
Evaluating Dry Eye and Meibomian Gland Dysfunction With Meibography in Patients With Stevens-Johnson Syndrome. 38
31205158 2019
72
Presumed Sulfonamide-Associated Uveitis With Stevens-Johnson Syndrome in a Quarter Horse Mare. 38
31133310 2019
73
A modified technique for bedside amniotic membrane application to the eyelid margins for Stevens-Johnson syndrome. 38
31109496 2019
74
Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions. 38
31201937 2019
75
HLA-associated antiepileptic drug-induced cutaneous adverse reactions. 38
30895730 2019
76
Contrast media and cutaneous reactions. Part 2: Delayed hypersensitivity reactions to iodinated contrast media. 38
31162717 2019
77
Severe Cutaneous Adverse Reactions during Tapering of High-Dose Systemic Steroid Therapy for Autoimmune Diseases: Implications for Non-HIV Immune Reconstitution Inflammatory Syndrome. 38
31275132 2019
78
[Anti-laminin 332 mucous membrane pemphigoid with irreversible ocular and tracheobronchial involvement : Delayed diagnosis of a severe autoimmune bullous disease]. 38
30963224 2019
79
Intravenous immunoglobulin treatment: Where do dermatologists stand? 38
30756448 2019
80
Drug-induced liver injury with skin reactions: Drugs and host risk factors, clinical phenotypes and prognosis. 38
30515930 2019
81
Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. 38
30282109 2019
82
Oseltamivir induced Stevens-Johnson syndrome/toxic epidermal necrolysis-case report. 38
31083216 2019
83
Carbonic anhydrase inhibitor-induced Stevens-Johnson syndrome/toxic epidermal necrolysis leads to extensive cutaneous involvement. 38
31128378 2019
84
Pancytopenia in a Patient with Stevens-Johnson Syndrome: A Case Report with Literature Review. 38
31355064 2019
85
Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series. 38
30430542 2019
86
Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics. 38
30395917 2019
87
Prosthetic Replacement of the Ocular Surface Ecosystem Treatment for Ocular Surface Disease in Pediatric Patients With Stevens-Johnson Syndrome. 38
30664843 2019
88
Galectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells. 38
31100551 2019
89
Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. 38
31066027 2019
90
Ophthalmic Manifestations of Mycoplasma-Induced Rash and Mucositis. 38
31246679 2019
91
Analysis of Cutaneous Adverse Drug Reactions Reported at the Regional ADR Monitoring Center. 38
31148872 2019
92
Interventions for erythema multiforme: a systematic review. 38
30680804 2019
93
Outpatient management and follow-up recommendations for adverse drug reactions: guidelines for posthospitalization care. 38
31233575 2019
94
Topical moxifloxacin-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. 38
31036782 2019
95
Allopurinol-Induced Stevens-Johnson Syndrome. 38
30638600 2019
96
[A Case of Stevens-Johnson Syndrome Induced by Chemotherapy for Metastatic Colon Cancer]. 38
31164523 2019
97
Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. 38
30840032 2019
98
Association of human antigen class I genes with cold medicine-related Stevens-Johnson syndrome with severe ocular complications in a Korean population. 38
30705045 2019
99
Expression of prostaglandin E2 receptor 3 in the eyelid epidermis of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
31000507 2019
100
Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Proportion and determinants of underreporting to pharmacovigilance. 38
30292922 2019
101
[Cutaneous Adverse Drug Reaction Caused by Antiepileptic Drug]. 38
30988229 2019
102
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. 38
30399387 2019
103
Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database. 38
30689189 2019
104
Spontaneous Resolution of Cholesteatoma in a Patient on Long-Term Infliximab. 38
30632386 2019
105
Spontaneous cutaneous adverse drug reaction reports-An analysis of a 10-year dataset in Singapore. 38
30911397 2019
106
[Lamotrigine induced hypersensitivity syndrome in children: a case report]. 38
30996382 2019
107
Stevens-Johnson syndrome. 38
30406877 2019
108
Scoring systems for allergies and asthma in clinical research and practice. 38
30563587 2019
109
Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. 38
30612819 2019
110
A Case of Stevens-Johnson Syndrome After Exposure to Valproic Acid. 38
30947405 2019
111
Sutureless amniotic membrane transplantation with cyanoacrylate glue for acute Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
30872140 2019
112
Corneal Limbal Stem Cell Deficiency in Children with Stevens-Johnson Syndrome. 38
30347185 2019
113
Novel complication of Flakka: Stevens-Johnson syndrome/Toxic epidermal necrolysis overlap. 38
30503281 2019
114
Bronchiolitis obliterans as a long-term sequela of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. 38
30908698 2019
115
A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016. 38
30908601 2019
116
Making Rash Decisions in Epilepsy: Evaluating Hypersensitivity Reactions to Anti-seizure Medications. 38
30955419 2019
117
Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population. 38
30826555 2019
118
Phenotypes of Severe Cutaneous Adverse Reactions Caused by Nonsteroidal Anti-inflammatory Drugs. 38
30661313 2019
119
Severe Cutaneous Adverse Reactions in Korean Pediatric Patients: A Study From the Korea SCAR Registry. 38
30661316 2019
120
Bullous fixed drug eruption: A potential diagnostic pitfall: a study of 18 cases. 38
31006486 2019
121
Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome. 38
30968035 2019
122
Ciprofloxacin-Induced Bullae of the Lower Extremity: A Case of a Fixed Drug Reaction. 38
31135195 2019
123
The rash that presents as target lesions. 38
30981295 2019
124
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn's disease: Need for a multidisciplinary approach. 38
30541717 2019
125
Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. 38
30782092 2019
126
Ocular Surface Reconstruction Using Circumferentially-trephined Autologous Oral Mucosal Graft Transplantation in Limbal Stem Cell Deficiency. 38
30746908 2019
127
Bronchiolitis Obliterans After Cefuroxime-Induced Stevens-Johnson Syndrome. 38
30737366 2019
128
Fluoxetine-induced Stevens-Johnson syndrome and liver injury. 38
30296343 2019
129
Spectrum of gastrointestinal involvement in Stevens - Johnson syndrome. 38
30788030 2019
130
Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis. 38
30129156 2019
131
Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. 38
30298362 2019
132
Comprehensive assessment of T cell receptor β repertoire in Stevens-Johnson syndrome/toxic epidermal necrolysis patients using high-throughput sequencing. 38
30623817 2019
133
Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea. 38
30666843 2019
134
Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data. 38
30254188 2019
135
Radiation-induced dermatitis after administration of mogamulizumab for adult T-cell leukaemia/lymphoma: a multi-institutional retrospective study. 38
30452692 2019
136
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview. 38
30058498 2019
137
Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization. 38
30468876 2019
138
Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma. 38
30729055 2019
139
Gene expression analysis of conjunctival epithelium of patients with Stevens-Johnson syndrome in the chronic stage. 38
31276031 2019
140
Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
30830062 2019
141
Prognostication Using SCORTEN Severity of Illness Score in Patients With Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. 38
30273718 2019
142
A Case Study of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis (SJS-TEN) Overlap in Mycoplasma pneumoniae-Associated Tracheobronchitis. 38
31275674 2019
143
Ocular and Mucocutaneous Sequelae among Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Togo. 38
30838038 2019
144
Ciprofloxacin-induced Stevens-Johnson Syndrome with Grapefruit Juice Consumption: A Case Report. 38
30868040 2019
145
Stevens-Johnson syndrome-like reaction without mucosal lesions associated with cyclophosphamide. 38
30504533 2019
146
A Review of the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 38
30702535 2019
147
Efficacy and safety of cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
30285308 2019
148
Stevens-Johnson Syndrome complicated by obstructive uropathy, pneumothorax, and pneumomediastinum: a case report and literature review. 38
31205959 2019
149
Outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and/or intravenous immunoglobulins in Pietermaritzburg, South Africa. 38
31308970 2019
150
Development of an electronic medical record-based algorithm to identify patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan. 38
31408480 2019
151
The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. 38
29569740 2019
152
Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens-Johnson syndrome. 38
29256167 2019
153
A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. 38
29859332 2019
154
Defining Regional Differences in Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Tool to Improve Drug Safety? 38
30120778 2019
155
Lacrimal passage irrigation in children with Stevens-Johnson syndrome or toxic epidermal necrolysis: a five-year retrospective study. 38
30658599 2019
156
Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. 38
30702955 2019
157
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study. 38
30112729 2019
158
Analysis of HLA-B Allelic Variation and IFN-γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs. 38
29800753 2019
159
Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea. 38
29466850 2019
160
Ocular Surface Microbial Flora in Patients with Chronic Limbal Stem Cell Deficiency Undergoing Cultivated Oral Mucosal Epithelial Transplantation. 38
31114120 2019
161
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. 38
30509740 2019
162
Anesthesia Considerations in Modified Osteo-odonto-keratoprosthesis. 38
29983007 2019
163
Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007⁻2018. 38
30658389 2019
164
Treatment of oral manifestations of toxic epidermal necrolysis with low-level laser therapy in a pediatric patient. 38
30474865 2019
165
Empyema Necessitans due to Interruption of Antituberculosis Treatment. 38
31275673 2019
166
A Computational Platform and Guide for Acceleration of Novel Medicines and Personalized Medicine. 38
30848462 2019
167
Controversies in drug allergy: Testing for delayed reactions. 38
30573342 2019
168
Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients. 38
30726458 2019
169
An Interesting Case of Carbamazepine-Induced Stevens-Johnson Syndrome. 38
30535610 2018
170
Major Histocompatibility Complex and Psoriasis. 38
30471757 2018
171
Stevens - Johnson syndrome (SJS) following Murunga leaf (Moringa oleifera) consumption 38
30669215 2018
172
Oxcarbazepine-Induced Stevens-Johnson Syndrome. 38
30605267 2018
173
Minimal clinically important differences for measures of treatment efficacy in Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
29890189 2018
174
Silver absorption in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis treated with silver-impregnated dressings. A case series. 38
29893032 2018
175
Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System. 38
30395352 2018
176
Stevens Johnson Syndrome with Vaginal Pain and Lesions as Initial Presentation. 38
30573724 2018
177
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report. 38
30301570 2018
178
Risks associated with lamotrigine prescription: a review and personal observations. 38
29480028 2018
179
Twelve years of Lyell's Syndrome in the burn unit of São João Hospital Centre. 38
30983925 2018
180
Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature. 38
30169429 2018
181
Topical mesalazine as a cause of Stevens-Johnson syndrome. 38
29931986 2018
182
Infectious Keratitis After Ocular Surface Stem Cell Transplantation. 38
30004958 2018
183
Oral isotretinoin for acne. 38
30484286 2018
184
Topical Treatment of Persistent Epithelial Defects with a Matrix Regenerating Agent. 38
30312119 2018
185
Stevens-Johnson Syndrome Induced by Pembrolizumab in a Lung Cancer Patient. 38
29885481 2018
186
Results of Detailed Investigations Into Stevens-Johnson Syndrome With Severe Ocular Complications. 38
30481825 2018
187
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. 38
29758282 2018
188
Chemistry-Wide Association Studies (CWAS): A Novel Framework for Identifying and Interpreting Structure-Activity Relationships. 38
30376324 2018
189
High-risk drug rashes. 38
29803714 2018
190
Propranolol eye drops in patients with corneal neovascularization. 38
30407290 2018
191
Erythema Multiforme Major After Immunotherapy With Diphenylcyclopropenone for Alopecia Areata. 38
30346328 2018
192
Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions. 38
30112775 2018
193
Outcomes of the Boston Type I Keratoprosthesis as the Primary Penetrating Corneal Procedure. 38
30157053 2018
194
Severe Dry Eye With Combined Mechanisms is Involved in the Ocular Sequelae of SJS/TEN at the Chronic Stage. 38
30481810 2018
195
Methotrexate-Induced Toxic Epidermal Necrolysis: A Rare Case Report and Review of Literature. 38
30405287 2018
196
Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. 38
29985833 2018
197
Microbial keratitis in Stevens-Johnson syndrome: Clinical and microbiological profile. 38
29981457 2018
198
Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
29601936 2018
199
Reply to: "Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need". 38
29913260 2018
200
Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need. 38
29913262 2018
201
The effect of levamisole in the treatment of recalcitrant recurrent erythema multiforme major: An observational study. 38
30143369 2018
202
Erythema multiforme major induced by exotic wood. 38
29987843 2018
203
Variants of Erythema Multiforme: A Case Report and Literature Review. 38
30564538 2018
204
Drug Allergy. 38
30308679 2018
205
A liver-immune coculture array for predicting systemic drug-induced skin sensitization. 38
30252012 2018
206
Evaluation of a lymphocyte transformation test and cytokine detection assay to identify phenytoin and carbamazepine provoked DRESS or SJS/TEN in epilepsy patients. 38
30103195 2018
207
Incidence, clinical features and diagnosis of cicatrising conjunctivitis in Australia and New Zealand. 38
29921954 2018
208
Pediatric Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Halted by Etanercept. 38
29421925 2018
209
A diagnosis of Stevens-Johnson Syndrome (SJS) in a patient presenting with superficial keratitis. 38
30128368 2018
210
A Case Report-Stevens-Johnson Syndrome as an Adverse Effect of Capecitabine. 38
28066869 2018
211
Erratum: Successful Treatment of Stevens-Johnson Syndrome with Cyclosporine and Corticosteroid: Correction. 38
30401993 2018
212
Corneal Ectasia in Stevens-Johnson Syndrome: A Sequela of Chronic Disease. 38
29890163 2018
213
Selective Use of Cyclosporine for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis May Exclude Patients with Poor Prognostic Factors. 38
29559345 2018
214
Incidence of Stevens-Johnson syndrome following combination drug use of allopurinol, carbamazepine and phenytoin in Taiwan: A case-control study. 38
29963717 2018
215
Association between HLA-B*44:03-HLA-C*07:01 haplotype and cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Thailand. 38
29706602 2018
216
Management of Severe Cicatricial Entropion With Labial Mucous Membrane Graft in Cicatricial Ocular Surface Disorders. 38
29762330 2018
217
A Study of Cutaneous Adverse Drug Reactions in a Tertiary Care Center in Punjab. 38
30258795 2018
218
Rechallenge of lamotrigine after development of rash. 38
30206509 2018
219
Active surveillance of severe cutaneous adverse reactions: A case-population approach using a registry and a health care database. 38
30051945 2018
220
Association Between Severe Acute Contact Dermatitis Due to Nigella sativa Oil and Epidermal Apoptosis. 38
30073256 2018
221
Reasons for inpatient admissions to the dermatology department in Lomé, Togo : Trends between 1992 to 2005 and 2005 to 2016. 38
30270828 2018
222
Toxic Epidermal Necrolysis: A Dermatologic Emergency and the Role of the Oral and Maxillofacial Surgeon. 38
29555183 2018
223
Paraneoplastic pemphigus associated with chronic lymphocytic leukemia: a case report. 38
30165900 2018
224
Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
29888432 2018
225
Procalcitonin as a diagnostic indicator for systemic bacterial infections in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
29897140 2018
226
A retrospective analysis of infections and antibiotic treatment in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
30095319 2018
227
A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine. 38
29762688 2018
228
Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Theranostics via Pharmacogenomics. 38
29652519 2018
229
A Case of Stevens-Johnson Syndrome Probably Induced by Herbal Medicine. 38
30065594 2018
230
Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: A meta-analysis. 38
30015149 2018
231
Erythema multiforme major with swollen lips and crusted erosions. 38
30152391 2018
232
A Novel Approach To Sealing The Denuded Dermis of the Abdominal Wall With A Negative Pressure Wound Device After A Decompressive Laparotomy. 38
28661985 2018
233
Successful Treatment of Stevens-Johnson Syndrome with Cyclosporine and Corticosteroid. 38
30186001 2018
234
Stevens-Johnson Syndrome: A Challenging Diagnosis. 38
30059372 2018
235
Stevens-Johnsons syndrome or drug-induced lupus - a clinical dilemma: A case report and review of the literature. 38
29930803 2018
236
Chemotherapy patient with Stevens-Johnson Syndrome presents to the Emergency Department: A case report. 38
29743141 2018
237
The Role of Biological Skin Substitutes in Stevens-Johnson Syndrome: Systematic Review. 38
30157125 2018
238
ISMP Adverse Drug Reactions: Propofol-Related Infusion Syndrome (PRIS)1,2; Ivermectin-Induced Stevens-Johnson Syndrome; Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis From Fexofenadine; Memantine-Related Drug Eruption. 38
30038437 2018
239
Stevens-Johnson syndrome/toxic epidermal necrolysis in Jewish and Arab populations. 38
29972250 2018
240
Anesthetic considerations in Stevens-Johnson syndrome with epilepsy for bilateral amniotic membrane grafting in eye. 38
30078868 2018
241
An Epidemiological Study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis during 2010-2015 at Shahid Faghihi Hospital, Shiraz, Iran. 38
30046212 2018
242
Carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a Filipino with positive HLA-B75 serotype. 38
30018035 2018
243
A Case of Toxic Epidermal Necrolysis Successfully Treated with Low Dose Intravenous Immunoglobulins and Systemic Corticosteroid. 38
30038738 2018
244
Maternal Serum Eye Drops in the Management of Pediatric Persistent Corneal Epithelial Defects: A Case Series. 38
29324584 2018
245
Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population. 38
29610831 2018
246
Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. 38
29559400 2018
247
Vitreoretinal Complications and Outcomes in 92 Eyes Undergoing Surgery for Modified Osteo-Odonto-Keratoprosthesis: A 10-Year Review. 38
29342438 2018
248
Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. 38
29274302 2018
249
A cross-sectional comparative study on chronic ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year case series. 38
28547534 2018
250
Stevens-Johnson Syndrome associated with methotrexate treatment for acute lymphoblastic leukemia: a case report. 38
29756724 2018
251
Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer. 38
29984280 2018
252
Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome. 38
30142712 2018
253
Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab. 38
29952288 2018
254
How Does SCORTEN Score? 38
29789855 2018
255
Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results. 38
29627131 2018
256
Variability in Management of Patients With SJS/TEN: A Survey of Burn Unit Directors. 38
29901804 2018
257
Up-Regulation of T-Cell Activation MicroRNAs in Drug-Specific CD4+ T-Cells from Hypersensitive Patients. 38
29644860 2018
258
Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients-Exposed/Unexposed and Propensity Score-Matched Analyses. 38
29369774 2018
259
Mycoplasma pneumoniae, more than a lung disease. 38
30142726 2018
260
[Drug reaction with eosinophilia and systemic symptoms due to carbamazepine. Pediatric case]. 38
29756718 2018
261
Stevens-Johnson syndrome and toxic epidermal necrolysis-like cutaneous presentation of chikungunya fever: A case series. 38
29573443 2018
262
Chronic Ocular Sequelae of Stevens-Johnson Syndrome in Children: Long-term Impact of Appropriate Therapy on Natural History of Disease. 38
29421293 2018
263
Stevens-Johnson Syndrome After Armodafinil Use. 38
29734973 2018
264
Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience. 38
29029855 2018
265
Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma. 38
30186133 2018
266
Ethosuximide-induced Stevens-Johnson syndrome: Beneficial effect of early intervention with high-dose corticosteroid therapy. 38
29430697 2018
267
Antibiotic Drug Use and the Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Population-Based Case-Control Study. 38
29273314 2018
268
Response: The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs: Comment on data sparsity. 38
29723402 2018
269
The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs: Comment on data sparsity. 38
29723404 2018
270
A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China. 38
29642234 2018
271
Drug-induced liver injury is frequently associated with severe cutaneous adverse drug reactions: experience from two Australian tertiary hospitals. 38
29316113 2018
272
Stevens-Johnson and Lyell syndromes in children in a hospital setting in Lomé, Togo, from 2000 to 2015. 38
29976535 2018
273
[Acute life-threatening drug reactions of the skin]. 38
29721625 2018
274
The HLA-B*15:02 polymorphism and Tegretol®-induced serious cutaneous reactions in epilepsy: An updated systematic review and meta-analysis. 38
29685430 2018
275
Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. 38
29092853 2018
276
Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome. 38
29528923 2018
277
First case of Stevens-Johnson syndrome after rabies vaccination. 38
29333656 2018
278
Autoimmune Progesterone Dermatitis Mistaken for Stevens-Johnson Syndrome. 38
29528935 2018
279
Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon? 38
29782303 2018
280
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. 38
29392710 2018
281
Limbal Stem Cell Deficiency-Demography and Underlying Causes. 38
29378178 2018
282
Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities. 38
29731949 2018
283
[Factors associated with the severity of acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa]. 38
29487020 2018
284
Notice of Retraction and Replacement: "Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome" (Drayer SM, Laufer LR, Farrell ME). 38
29533269 2018
285
Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-analysis. 38
29541744 2018
286
A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia. 38
29703869 2018
287
[Severe skin reactions due to new medications]. 38
29568997 2018
288
Ocular toxoplasmosis: adverse reactions to treatment in a Brazilian cohort. 38
29788193 2018
289
HLA-A*31:01 and Oxcarbazepine-Induced DRESS in a Patient With Seizures and Complete DCX Deletion. 38
29610167 2018
290
Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins). 38
29636107 2018
291
Stevens-Johnson syndrome induced by modafinil. 38
29028129 2018
292
Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
29315761 2018
293
Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. 38
29105735 2018
294
Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines! 38
29692452 2018
295
Chronic ocular complications of Stevens-Johnson syndrome associated with causative medications in Korea. 38
28988785 2018
296
Severe Physical Complications among Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 38
29052094 2018
297
Specific association of the rs6500265 and rs9933632 single-nucleotide polymorphisms in Japanese patients with antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements. 38
29239905 2018
298
Acute generalized exanthematous pustulosis simulating Stevens-Johnson syndrome/toxic epidermal necrolysis associated with the use of vismodegib. 38
29387760 2018
299
Lamotrigine Rechallenge in Treatment-Resistant Bipolar Disorder. 38
29659202 2018
300
Successful drug desensitization in patients with delayed-type allergic reactions to anti-tuberculosis drugs. 38
29410254 2018
301
Histopathology of Cutaneous Inflammatory Disorders in Children. 38
29607753 2018
302
Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management. 38
29574562 2018
303
Atypical Hand, Foot, and Mouth Disease Caused by Coxsackievirus A6 in Denmark: A Diagnostic Mimicker. 38
29182793 2018
304
Mycoplasma pneumoniae-induced mucositis without rash in an 11-year-old boy. 38
29531742 2018
305
Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch? 38
29181714 2018
306
Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. 38
29400697 2018
307
Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 38
29188475 2018
308
Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide. 38
29445458 2018
309
EyePrintPRO therapeutic scleral contact lens: indications and outcomes. 38
29426444 2018
310
Selected presentations of lip enlargement: clinical manifestation and differentiation. 38
29599668 2018
311
Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database. 38
28963996 2018
312
Ocular surface cytokine profile in chronic Stevens-Johnson syndrome and its response to mucous membrane grafting for lid margin keratinisation. 38
28689166 2018
313
Survey of Nonprescription Medication and Antibiotic Use in Patients with Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Overlap Syndrome. 38
29389866 2018
314
ISMP Adverse Drug Reactions: Influenza Vaccine-Induced Stevens-Johnson Syndrome; Vilazodone-Induced Nightmares; Dabigatran-Induced Pustular Eruptions; Neurotoxic and Cardiotoxic Symptoms After Cannabis Concentrate Exposure; Rosuvastatin-Induced Skin Eruption. 38
29434381 2018
315
Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population. 38
29176400 2018
316
[STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS AS A PARA-NEOPLASTIC SYNDROME FOR B-CELL LYMPHOMA]. 38
29484861 2018
317
Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib. 38
29328518 2018
318
Salazosulphapyridine-related Stevens-Johnson Syndrome Caused by Sulphapyridine and Confirmed by Enzyme-linked Immunospot Assay. 38
29126103 2018
319
Stevens-Johnson Syndrome During Pregnancy: Case Report of a Newborn Treated With the Culprit Drug. 38
29261833 2018
320
Mycoplasma pneumoniae-associated Fuchs syndrome. 38
29445492 2018
321
Allopurinol suppresses expression of the regulatory T-cell migration factors TARC/CCL17 and MDC/CCL22 in HaCaT keratinocytes via restriction of nuclear factor-κB activation. 38
28949055 2018
322
Mucocutaneous inflammation in the Ikaros Family Zinc Finger 1-keratin 5-specific transgenic mice. 38
28914974 2018
323
Overexpression of cytotoxic proteins correlates with liver function impairment in patients with drug reaction with eosinophilia and systemic symptoms (DRESS). 38
29521632 2018
324
External quality assessment for laboratory testing of HLA-B*15:02 allele in relation to carbamazepine therapy. 38
28440597 2018
325
Cataract surgery in ocular surface diseases: clinical challenges and outcomes. 38
29210839 2018
326
Efficacy and adverse events of oral isotretinoin for acne: a systematic review. 38
28542914 2018
327
The use of cyclosporine for Stevens-Johnson syndrome-toxic epidermal necrolysis spectrum at the University of Louisville: A case series and literature review. 38
29469760 2018
328
Lamotrigine-Valproic Acid Interaction Leading to Stevens-Johnson Syndrome. 38
30228819 2018
329
Stevens-Johnson syndrome during nivolumab treatment of NSCLC. 38
29045532 2018
330
Influenza B virus infection and Stevens-Johnson syndrome. 38
29282756 2018
331
Corrigendum to "The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China". 38
30050956 2018
332
A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
29636627 2018
333
The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China. 38
29607330 2018
334
Severe Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome-beyond skin involvement. 38
29159901 2018
335
Tolerance Induction to Antituberculosis Drugs in a Patient With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap. 38
30083412 2018
336
Life-threatening dermatoses: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Impact on the Spanish public health system (2010-2015). 38
29912947 2018
337
Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database. 38
29387340 2018
338
Diverse expression of TNF-α and CCL27 in serum and blister of Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
29713456 2018
339
Vancomycin-Induced Stevens-Johnson Syndrome in a Boy Under 2 Years Old: An Early Diagnosis by Granulysin Rapid Test. 38
29594082 2018
340
The influence of acute kidney injury on the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis: The prognostic value of KDIGO staging. 38
30192870 2018
341
The association of HLA B*15:02 allele and Stevens-Johnson syndrome/toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population. 38
29076187 2018
342
Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital. 38
29853855 2018
343
The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study. 38
29148124 2018
344
Nursing care of a boy seriously infected with Steven-Johnson syndrome after treatment with azithromycin: A case report and literature review. 38
29505509 2018
345
Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies. 38
29577050 2018
346
Anterior segment optical coherence tomography findings in type I Boston keratoprosthesis. 38
29538593 2018
347
Vaccine-induced toxic epidermal necrolysis: A case and systematic review. 38
29469759 2018
348
SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. 38
29310768 2018
349
Bullous Fixed Drug Eruption Following Ibuprofen Ingestion. 38
29756000 2018
350
Mycoplasma pneumoniae-associated Mucositis: A Recently Described Entity. 38
30755992 2018
351
An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. 38
29651444 2018
352
A Comparison of Adverse Drug Reaction Profiles in Patients on Antiretroviral and Antitubercular Treatment in Zimbabwe. 38
28965312 2018
353
Effects of piroxicam on tissue distribution of sulfadimidine in West African Dwarf male and female goats. 38
28176534 2018
354
Bullous Pemphigoid-like Skin Eruption during Treatment with Rivaroxaban: A Clinical Case Study. 38
30756013 2018
355
Staphylococcal scalded skin syndrome in a 4-year-old child: a case report. 38
29378637 2018
356
[Adverse cutaneous reactions to drugs]. 38
29368897 2018
357
Boston Type I Keratoprosthesis Implantation Following Autologous Submandibular Gland Transplantation for End Stage Ocular Surface Disorders. 38
27726460 2018
358
A Rare Case Report of Toxic Epidermal Necrolysis Due to Ofloxacin. 38
29506464 2018
359
Hemophagocytic lymphohistiocytosis in an infant with multiple triggers!! 38
29563683 2018
360
[Fatal Toxic Epidermal Necrolysis Induced by Diclofenac Re-Administration in the Teaching Hospital of Bouaké (Côte d'Ivoire)]. 38
30763502 2018
361
Association Between HLA genotypes and Oxcarbazepine-induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-Analysis. 38
29370880 2018
362
The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation. 38
28648978 2018
363
Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study. 38
28658503 2018
364
Cutaneous drug reactions to antiepileptic drugs and relation with HLA alleles in the Turkish population. 38
29350020 2018
365
Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. 38
29844705 2018
366
Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients. 38
29546073 2018
367
CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment. 38
29636628 2018
368
Adverse Drug Reaction Onsets in Uganda's VigiBase®: Delayed International Visibility, Data Quality and Illustrative Signal Detection Analyses. 38
30546260 2018
369
HLA Pharmacogenetic Markers of Drug Hypersensitivity in a Thai Population. 38
30127801 2018
370
A New Search Method Using Association Rule Mining for Drug-Drug Interaction Based on Spontaneous Report System. 38
29593533 2018
371
A New Isolation Method of Human Lacrimal Canaliculus Epithelial Stem Cells by Maintaining Close Association with Their Niche Cells. 38
30275751 2018
372
A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects. 38
29515387 2018
373
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 38
29238841 2017
374
Functional SNP allele discovery (fSNPd): an approach to find highly penetrant, environmental-triggered genotypes underlying complex human phenotypes. 38
29202707 2017
375
[Skin pigmentation induced by meropenem and levofloxacin]. 38
29031417 2017
376
Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. 38
28885988 2017
377
Elevated Aqueous Cytokine Levels in Eyes With Ocular Surface Diseases. 38
28988898 2017
378
Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis drug reaction, and correlation with disease severity. 38
28940568 2017
379
Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. 38
29053440 2017
380
The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. 38
29027197 2017
381
Cutaneous manifestation mimicking Stevens-Johnson syndrome in a critically ill patient: looks similar but totally different. 38
29226836 2017
382
Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. 38
28831528 2017
383
Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic. 38
28412864 2017
384
Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study. 38
28423957 2017
385
Minor Salivary Gland Transplantation for Severe Dry Eyes. 38
28922328 2017
386
Characterization of enhancers and the role of the transcription factor KLF7 in regulating corneal epithelial differentiation. 38
28916725 2017
387
Pseudomelanomas Following Stevens-Johnson Syndrome. 38
28763334 2017
388
The use of Biobrane® for wound coverage in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 38
28526303 2017
389
Association of Human Leukocyte Antigen Class 1 genes with Stevens Johnson Syndrome with severe ocular complications in an Indian population. 38
29162886 2017
390
Letter to the Editor re: 'Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up'. 38
28626892 2017
391
Pustular erythema multiforme major associated with atypical pneumonia. 38
28543859 2017
392
Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome. 38
28885418 2017
393
Toxic epidermal necrolysis: a paradigm of critical illness. 38
29340540 2017
394
Chandelier scleral buckling for retinal detachment in Stevens-Johnson syndrome. 38
28985832 2017
395
Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. 38
28144971 2017
396
Role of Scleral Contact Lenses in Management of Coexisting Keratoconus and Stevens-Johnson Syndrome. 38
28749897 2017
397
Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
28314701 2017
398
Prognosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
28917480 2017
399
Reply to: "Prognosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis". 38
28917481 2017
400
A case of erythema multiforme major following administration of ciprofloxacin ophthalmic drops. 38
29469784 2017
401
Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia. 38
28346659 2017
402
[Epicutaneous patch testing in delayed drug hypersensitivity reactions induced by antiepileptic drugs]. 38
28416298 2017
403
Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility. 38
28689274 2017
404
Management of patients with ocular manifestations in vesiculobullous disorders affecting the mouth. 38
27717107 2017
405
[Severe cutaneous drug reactions in children]. 38
28932875 2017
406
Cutaneous Adverse Drug Reactions to Lamotrigine and Human Leukocyte Antigen Typing in North Indian Patients: A Case Series. 38
29184346 2017
407
[The major SCAR syndromes]. 38
29058836 2017
408
New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis. 38
28941473 2017
409
Severe cutaneous adverse reactions to drugs. 38
28476287 2017
410
Characterization of Children With Recurrent Episodes of Stevens Johnson Syndrome. 38
28339562 2017
411
Common allergies do not influence the prevalence of cutaneous hypersensitivity reactions to antiepileptic drugs. 38
28552676 2017
412
Successful Use of Cyclosporin A for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Three Children. 38
28884910 2017
413
Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiological and clinical outcomes analysis in public hospitals. 38
29166503 2017
414
T-cell activation in two cases of Stevens-Johnson syndrome after receiving amoxicillin-clavulanic acid. 38
28599076 2017
415
Vaginal Reconstruction for Vaginal Obliteration Secondary to Stevens Johnson Syndrome: A Case Report and Review of Literature. 38
29026478 2017
416
Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort. 38
28549953 2017
417
Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab. 38
29469720 2017
418
Stevens-Johnson syndrome secondary to isolated albuterol use. 38
28961298 2017
419
Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. 38
28438440 2017
420
Drug-induced Stevens-Johnson syndrome in Indian population: A multicentric retrospective analysis. 38
28891542 2017
421
Data Sparsity in Study on Human Leukocyte Antigen Class I Genes Associated With Stevens-Johnson Syndrome and Severe Ocular Complications. 38
28715524 2017
422
Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
27040133 2017
423
Data Sparsity in Study on Human Leukocyte Antigen Class I Genes Associated With Stevens-Johnson Syndrome and Severe Ocular Complications-Reply. 38
28715516 2017
424
Hypersensitivity to antipyretics: pathogenesis, diagnosis, and management. 38
28684647 2017
425
Mycoplasma pneumoniae-induced rash and mucositis: a recently described entity. 38
28830900 2017
426
Mycoplasma pneumoniae-associated mucositis syndrome: A rare and clinically challenging disease in a Saudi child. 38
31435263 2017
427
Bedside diagnostics in dermatology: Parasitic and noninfectious diseases. 38
28711083 2017
428
Methotrexate-induced epidermal necrosis: A case series of 24 patients. 38
28499754 2017
429
CD8+ T-cell activation by methazolamide causes methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
28295713 2017
430
Cefepime Associated With Phenytoin Induced Stevens-Johnson Syndrome. 38
28692440 2017
431
Toxic epidermal necrolysis in a child with lupus-associated pancreatitis. 38
28239770 2017
432
Stevens-Johnson syndrome and toxic epidermal necrolysis in childhood-onset systemic lupus erythematosus patients: a multicenter study. 38
28375199 2017
433
HLA-A*31: 01 and HLA-B*15:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population. 38
28570299 2017
434
Burn Center Care of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 38
28576247 2017
435
Causative Drugs of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Israel. 38
28181259 2017
436
Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions. 38
28295240 2017
437
Score of Toxic Epidermal Necrosis Predicts the Outcomes of Pediatric Epidermal Necrolysis. 38
28508417 2017
438
Mucositis Secondary to Chlamydia pneumoniae Infection: Expanding the Mycoplasma pneumoniae-Induced Rash and Mucositis Concept. 38
28568680 2017
439
Aprepitant for refractory nivolumab-induced pruritus. 38
28577951 2017
440
Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. 38
28391407 2017
441
Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population. 38
28509689 2017
442
Long-term safety experience with bendamustine for injection in a real-world setting. 38
28395515 2017
443
Infliximab after Boston Keratoprosthesis in Stevens-Johnson Syndrome: An Update. 38
27015032 2017
444
Oxcarbazepine-induced Stevens-Johnson syndrome: a pediatric case report. 38
28580160 2017
445
Conjunctival impression cytology evaluation of patients with dry eye disease using scleral contact lenses. 38
28089075 2017
446
Amniotic membrane transplants in the pediatric population. 38
28450179 2017
447
Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study. 38
28524050 2017
448
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Induced by Fexofenadine. 38
28570227 2017
449
Topical moxifloxacin-induced Stevens-Johnson syndrome. 38
28732631 2017
450
Reply: Topical moxifloxacin-induced Stevens-Johnson syndrome. 38
28732633 2017
451
Stevens-Johnson syndrome probably induced by ambroxol. 38
28436553 2017
452
The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. 38
28202399 2017
453
Characterization of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Admitted to Kenyatta National Hospital: A Retrospective Cross-Sectional Study. 38
28401493 2017
454
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group. 38
28296986 2017
455
Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. 38
28329382 2017
456
Stevens - Johnson Syndrome Induced by Combination of Lamotrigine and Valproic Acid in a 9-Year-Old Boy. 38
28952676 2017
457
Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome). 38
27487073 2017
458
Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children: 20 years study in a tertiary care hospital. 38
27650525 2017
459
Epidemiology and Molecular Characteristics of Mycoplasma pneumoniae During an Outbreak of M. pneumoniae-associated Stevens-Johnson Syndrome. 38
28060039 2017
460
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. 38
28439852 2017
461
Novel interferon-γ enzyme-linked immunoSpot assay using activated cells for identifying hypersensitivity-inducing drug culprits. 38
28330775 2017
462
Change in vault during scleral lens trials assessed with anterior segment optical coherence tomography. 38
28366677 2017
463
HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. 38
28476759 2017
464
Incidence of cutaneous adverse drug reactions among medical inpatients of Sultanah Aminah Hospital Johor Bahru. 38
28733562 2017
465
Stevens-Johnson syndrome in childhood. 38
27899204 2017
466
Delirious State and Agitation Following Heparin Induced Stevens-Johnson Syndrome. 38
28658886 2017
467
Suicidal behaviors in the dermatology patient. 38
28511829 2017
468
Fever in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Cases: Laboratory Work-up and Antibiotic Therapy. 38
28403057 2017
469
Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study. 38
28366923 2017
470
Microbiological findings and antibacterial therapy in Stevens-Johnson syndrome/toxic epidermal necrolysis patients from a Swedish Burn Center. 38
28075032 2017
471
Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone. 38
28108296 2017
472
Renal replacement therapy during Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective observational study of 238 patients. 38
27510226 2017
473
In vivo reflectance confocal microscopy of erythema multiforme and Stevens-Johnson syndrome: a histopathological correlation based on a case series. 38
28485871 2017
474
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done. 38
28411832 2017
475
Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study. 38
28499410 2017
476
Combined spinal-epidural anaesthesia for urgent caesarean section in a parturient with Stevens-Johnson syndrome. 38
28202310 2017
477
Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. 38
28285784 2017
478
Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 38
28011147 2017
479
Overlapping DRESS and Stevens-Johnson Syndrome: Case Report and Review of the Literature. 38
28611628 2017
480
Retrospective Analysis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 88 Chinese Patients. 38
28469101 2017
481
Association of human leukocyte antigen variants and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis. 38
28438823 2017
482
Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. 38
28483310 2017
483
Severe cutaneous adverse drug reactions of Chinese inpatients: a meta-analysis. 38
29186246 2017
484
Ivermectin induced Steven-Johnsons syndrome: case report. 38
28482929 2017
485
Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study. 38
28351788 2017
486
Eruptive melanocytic nevi during azathioprine therapy for antisynthetase syndrome. 38
28492593 2017
487
Are steroids effective in toxic epidermal necrolysis and Stevens-Johnson syndrome? 38
28430767 2017
488
Validation of Stevens-Johnson syndrome or toxic epidermal necrolysis diagnoses in the Clinical Practice Research Datalink. 38
27868282 2017
489
Genetics and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: What Have We Learned? 38
28278317 2017
490
Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis in adults. 38
27868186 2017
491
Genome-wide association study using the ethnicity-specific Japonica array: identification of new susceptibility loci for cold medicine-related Stevens-Johnson syndrome with severe ocular complications. 38
28100913 2017
492
Human Leukocyte Antigen Class I Genes Associated With Stevens-Johnson Syndrome and Severe Ocular Complications Following Use of Cold Medicine in a Brazilian Population. 38
28278336 2017
493
Piperacillin-tazobactam-induced linear IgA bullous dermatosis presenting clinically as Stevens-Johnson syndrome/toxic epidermal necrolysis overlap. 38
28084616 2017
494
The effect of comorbidities on overall mortality in Stevens- Johnson Syndrome: an analysis of the Nationwide Inpatient Sample. 38
28541871 2017
495
Acute Generalized Erythrodermic Pustular Psoriasis Associated with Bupropion/Naltrexone (Contrave®). 38
28130024 2017
496
Amniotic Membrane Transplantation for Corneal and Conjunctival Diseases: Classification of Application and Outcomes from Analysis of 95 cases. 38
30070444 2017
497
Paediatric Erythema Multiforme: Epidemiological, Clinical and Laboratory Characteristics. 38
27868144 2017
498
Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia. 38
27789188 2017
499
Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. 38
28062682 2017
500
The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. 38
27916277 2017
501
Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. 38
27992698 2017
502
A study of HLA-B*15:02 in 9 different Chinese ethnics: Implications for carbamazepine related SJS/TEN. 38
28205426 2017
503
Delayed Stevens-Johnson Syndrome Secondary to the Use of Lamotrigine in Bipolar Mood Disorder. 38
28515564 2017
504
Russian Keratoprosthesis in Stevens-Johnson Syndrome. 38
27941382 2017
505
Imatinib mesylate-induced lichenoid drug eruption. 38
28398413 2017
506
Topical Coenzyme Q10 Eye Drops as an Adjuvant Treatment in Challenging Refractory Corneal Ulcers: A Case Series and Literature Review. 38
26783983 2017
507
Eyelid Mass in Boston Keratoprosthesis Type 2. 38
27163939 2017
508
Reply: amniotic membrane transplantation in Stevens-Johnson syndrome. 38
27751824 2017
509
Amniotic membrane transplantation in Stevens-Johnson syndrome. 38
27746325 2017
510
[In vivo confocal microscopic observation of corneal changes in patients with chronic Stevens-Johnson syndrome or toxic epidermal necrolysis]. 38
28316191 2017
511
HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis. 38
28358139 2017
512
Nationwide Survey of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children in the United States. 38
27990674 2017
513
Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. 38
26927288 2017
514
Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
28153080 2017
515
Stevens-Johnson Syndrome-A Look Back. 38
30974457 2017
516
Methotrimeprazine-Associated Stevens-Johnson Syndrome in 2 Ashkenazi Jewish Patients. 38
28027113 2017
517
Stevens-Johnson syndrome and abuse of anabolic steroids. 38
28280713 2017
518
The use of intravenous immunoglobulins in Stevens-Johnson syndrome and toxic epidermal necrolysis: caution needed. 38
27868184 2017
519
Stevens Johnson syndrome/toxic epidermal necrolysis after exogenous contact to S,S-dimethyl cyanoimidodithiocarbonate. 38
27401191 2017
520
Poor reporting and documentation in drug-associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis - Lessons for medication safety. 38
27558920 2017
521
[Stevens-Johnson syndrome/toxic epidermal necrolysis after initiation of carbamazepine in a HLA-B*15:02 gene carrier – screening in risk patients is recommended]. 38
28221394 2017
522
Human leukocyte antigen and idiosyncratic adverse drug reactions. 38
28017537 2017
523
Patch testing - a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics. 38
27477905 2017